Hostname: page-component-78c5997874-lj6df Total loading time: 0 Render date: 2024-11-05T02:41:50.817Z Has data issue: false hasContentIssue false

Reduced activity of angiotensin-converting enzyme in basal ganglia in early onset schizophrenia1

Published online by Cambridge University Press:  09 July 2009

Alberto Arregui*
Affiliation:
MRC Neurochemical Pharmacology Unit, Cambridge
Angus V. P. Mackay
Affiliation:
MRC Neurochemical Pharmacology Unit, Cambridge
Ernest G. Spokes
Affiliation:
MRC Neurochemical Pharmacology Unit, Cambridge
Leslie L. Iversen
Affiliation:
MRC Neurochemical Pharmacology Unit, Cambridge
*
2Address for correspondence: Dr A. Arregui Department of Neurology, The Johns Hopkins Hospital, Baltimore, Maryland 21205, USA.

Synopsis

The dipeptidyl peptidase, angiotensin-converting enzyme (EC 3.4.15.1), was measured in various regions of post-mortem brains. Results from 51 patients with the hospital diagnosis of schizophrenia who were divided into the clinical categories of ‘schizophrenia’ and ‘schizophrenialike’ illness on the basis of case-note analysis were compared with those from 40 control subjects. A significant reduction in angiotensin-converting enzyme activity was observed only in the substantia nigra pars reticulata and in the lateral and medial segments of globus pallidus in the ‘schizophrenia’ group, with no significant differences in enzyme activity in substantia nigra pars compacta, caudate nucleus, nucleus accumbens, subthalamic nucleus or cerebellar cortex. Reduced enzyme activity was not seen in the ‘schizophrenia-like’ group, and occurred most significantly in ‘schizophrenia’ patients in whom the onset of the illness had occurred between the ages of 15 and 24 years. In the control population the activity of angiotensin-converting enzyme in substantia nigra pars reticulata decreased significantly with age. It is possible that patients with early onset ‘schizophrenia’ may represent a separate disease entity, rather than belonging to a spectrum of a single disease.

Type
Research Article
Copyright
Copyright © Cambridge University Press 1980

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

1

Address for reprints: MRC Neurochemical Pharma-coiogy Unit, Hills Road, Cambridge CB2 2QD.

References

Arregui, A., Bennett, J. P. Jr, Bird, E. D., Yamamura, H. I., Iversen, L. L. & Snyder, S. H. (1977). Huntington' s chorea: selective depletion of angiotensin converting enzyme in the corpus striatum. Annals of Neurology 2, 294298.CrossRefGoogle ScholarPubMed
Arregui, A., Emson, P. C. & Spokes, E. G. (1978). Angiotensin-converting enzyme in substantia nigra: reduction of activity in Huntington's disease and after intrastriatal kainic acid in rats. European Journal of Pharmacology 52, 121124.CrossRefGoogle ScholarPubMed
Arregui, A., MacKay, A. V. P., Iversen, L. L. & Spokes, E. G. (1979). Letter: Reduction of angiotensin-converting enzyme in substantia nigra in early onset schizophrenia. New England Journal of Medicine 300, 502503.Google ScholarPubMed
Benuck, M. & Marks, N. (1978). Inhibition of brain angiotensin- I converting enzyme by Bothrops jararacanonapeptide (SQ 20881) and a prolyl analogue (SQ 14225). Journal of Neurochemistry 30, 16531655.CrossRefGoogle Scholar
Bird, E. D. & Iversen, L. L. (1974). Huntington's chorea: post-mortem measurement of glutamic decarboxylase, choline acetyltransferase and dopamine in basal ganglia. Brain 97, 457472.CrossRefGoogle ScholarPubMed
Bird, E. D., Spokes, E. G., Barnes, J., MacKay, A. V. P., Iversen, L. L. & Shepherd, M. (1977). Increased brain dopamine and reduced glutamic acid decarboxylase and choline acetyltransferase activity in schizophrenia and related psychosis. Lancet ii, 11571159.CrossRefGoogle Scholar
Bird, E. D., Spokes, E. G. & Iversen, L. L. (1979). Increased dopamine concentration in limbic areas of brain from patients dying with schizophrenia. Brain 102, 347360.CrossRefGoogle ScholarPubMed
Bleuler, E. (1911). Dementia Praecox or the Group of Schizophrenias (trans. Zinkin, J., 1950). International Universities Press: New York.Google Scholar
Bruyn, G. (1971). Huntington' s chorea: historical, clinical and laboratory synopsis. In Diseases of the Basal Ganglia (ed. Vinken, P. J. and Bruyn, G.), pp. 298378. North Holland Publishing Company: Amsterdam.Google Scholar
Buckley, J. P. (1977). Central vasopressor actions of angiotensin. Biochemical Pharmacology 26, 13.CrossRefGoogle ScholarPubMed
Erdös, E. G. (1977). The angiotensin-I converting enzyme. Federation Proceedings 36, 17601765.Google ScholarPubMed
Fitzsimons, J. T. (1976). The physiological basis of thirst. Kidney International 10, 311.CrossRefGoogle ScholarPubMed
Kraepelin, E. (1896). Psychiatric ein Lehrbuchfür Studierende und Ärzte. Barth: Leipzig.Google Scholar
Poth, M. M., Heath, R. G. & Ward, M. (1975). Angiotensinconverting enzyme in human brain. Journal of Neurochemistry 25, 8385.CrossRefGoogle ScholarPubMed
Richter, D. (1976). The impact of biochemistry on the problem of schizophrenia. In Schizophrenia Today (ed. Kemali, D., Bartholini, G. and Richter, D.), pp. 7183. Pergamon Press: Oxford.CrossRefGoogle Scholar
Severs, W. B. & Daniels-Severs, A. E. (1973). Effects of angiotensin on the central nervous system. Pharmacological Reviews 25, 415449.Google ScholarPubMed
Soffer, R. L. (1976). Angiotensin-converting enzyme and the regulation of vasoactive peptides. Annual Review of Biochemistry 45, 7394.CrossRefGoogle ScholarPubMed
Spokes, E. G. S. (1979). An analysis of factors influencing measurements of dopamine, noradrenaline, glutamic acid decarboxylase and choline acetylase in human postmortem brain. Brain 102, 333346.CrossRefGoogle Scholar
Wing, J. K., Cooper, J. E. & Sartorius, N. (1974). The Measurement and Classification of Psychiatric Symptoms. Cambridge University Press: London.Google Scholar
Yang, H.-Y. T. & Neff, N. H. (1972). Distribution and properties of angiotensin converting enzyme of rat brain. Journal of Neurochemistry 19, 24432450.CrossRefGoogle ScholarPubMed